NCT04324112View on ClinicalTrials.gov

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 28, 2020

Primary Completion Date

April 30, 2028

Study Completion Date

July 31, 2028

Conditions
Hairy Cell Leukemia
Interventions
DRUG

binimetinib

Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.

DRUG

Encorafenib

Encorafenib will be given orally at a dose of 450mg QD continuously for 28-day cycles with no resting period between cycles.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH